SCHEMBL15919265

SCHEMBL15919265

COC(=O)c1cc(-c2ccc(-c3ccc(OCCNC(=O)C(C)C)cc3)cc2)nc2ccncc12

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 7/20 0.55
KDM4E B2RXH2 6/20 0.45
ALDH1A1 P00352 6/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PDE10A Q9Y233 1/20 0.43
TP53 P04637 2/20 0.43
DHODH Q02127 1/20 0.41
GAA P10253 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
HPGD P15428 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 1/20 0.41
MCL1 Q07820 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15905252 0.90 LMNA (0.45) PLA2G2AKDM4EALDH1A1SMN1; SMN2PDE10A
SCHEMBL15905052 0.88 TP53 (0.48) PLA2G2AKDM4EALDH1A1SMN1; SMN2PDE10A
SCHEMBL17323663 0.87 PLA2G2A (0.59) PLA2G2AKDM4EALDH1A1SMN1; SMN2PDE10A
SCHEMBL15919256 0.86 PLA2G2A (0.53) PLA2G2AKDM4EALDH1A1SMN1; SMN2PDE10A
SCHEMBL15919255 0.85 PLA2G2A (0.60) PLA2G2AKDM4EALDH1A1SMN1; SMN2PDE10A
SCHEMBL17327507 0.84 PLA2G2A (0.56) PLA2G2AKDM4EALDH1A1SMN1; SMN2PDE10A
Hydrochloric Acid SCHEMBL17313806 0.84 PLA2G2A (0.59) PLA2G2AKDM4EALDH1A1SMN1; SMN2PDE10A
SCHEMBL15904842 0.84 PLA2G2A (0.62) PLA2G2AKDM4EALDH1A1SMN1; SMN2PDE10A
SCHEMBL17323662 0.84 PLA2G2A (0.57) PLA2G2AKDM4EALDH1A1SMN1; SMN2PDE10A
SCHEMBL15919257 0.83 PLA2G2A (0.55) PLA2G2APDE10ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO PLA2G2A 1990/4885KDM4E 3322/4885ALDH1A1 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.